Oculis

Dry Eye Awareness Month highlights this prevalent disease affecting nearly 40 million people in the United States alone and can lead to ocular discomfort, fatigue, and visual disturbances, significantly impacting their quality of life. A recent report showed that the vast majority of patients (87%) don’t feel that their chronic dry eye disease is well-managed with current treatment options. As a company focused on saving sight and improving eye care, we are committed to advancing innovative treatments for diseases such as DED. To learn more, check out this recent Q&A in @Healio with Riad SHERIF, MD, our CEO, and Dr. Anat Galor, Professor of Ophthalmology at the Bascom Palmer Eye Institute, University of Miami, discussing the recent positive topline results from the phase 2b RELIEF trial with licaminlimab, Oculis’ novel anti-TNF-α eye drop, and highlighting the Company’s #PrecisionMedicine approach that has the potential to transform the current treatment paradigm for DED: https://lnkd.in/evsRQXMJ   #Ophthalmology #DryEyeAwarenessMonth #DryEye #EyeHealth #Biotech

EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has established the Ramin Tadayoni Award supported by Oculis. Professor Tadayoni was a world-renowned retina specialist who contributed greatly to the field of ophthalmology and to Oculis’ success as Retina Chair of the company’s Scientific Advisory Board and as Chief Scientific Officer, at the time of his unexpected passing earlier this year. Throughout his career, Professor Tadayoni was highly committed to advancing retinal research and education. This annual award will combine both of these profound values by supporting the next generation of talented ophthalmologists who have demonstrated outstanding potential in retinal research and are driving forward innovation in the field. For additional details on this announcement, see our press release here: https://bit.ly/4ezIZY9 For more information about the Ramin Tadayoni Award, including eligibility requirements and how to apply, visit: https://lnkd.in/eFgZen6f #eyehealth #ophthalmology #biotech #biopharma #eyedisease #education #researchgrant

Following our recent Phase 2 RELIEF data for licaminlimab (also known as OCS-02), our novel anti-TNFα antibody eye drop candidate, the Oculis team had the opportunity to attend the 2024 @European Dry Eye Society Congress (#EuDEC 2024). We enjoyed the opportunity to discuss the data, which delivered further evidence to support the potential of our #PrecisionMedicine approach for the treatment of dry eye disease (#DED), a growing area of unmet need that affects nearly 40 million people in the US alone.   The RELIEF trial was an exploratory study designed to achieve three specific objectives: to evaluate the efficacy of licaminlimab on the signs of DED, to confirm the TNFR1 genetic biomarker as a predictor of response and to select the primary sign efficacy endpoint for a future Phase 3 trial. The trial met all three of these objectives, with positive topline data complementing two prior successful Phase 2 studies, during which the TNFR1 genetic biomarker was identified as a predictor of high responders to therapy. Excitingly, improvement of multiple signs of DED were observed in the full trial population, with more pronounced effect in the subpopulation with a TNFR1-related genotype, consistent with earlier trial results and laying the groundwork for progression towards a Phase 3 study.   For more information on the RELIEF topline results including important information on forward-looking statements, see our press release here: ur press release here: https://bit.ly/4bWdQw0

We are thrilled to welcome industry leaders, @Robert K. Warner and Dr. Arshad M. Khanani, to our Board of Directors. Mr. Warner, who brings substantial global and U.S. commercial leadership expertise, and Dr. Khanani, a world-renowned retina expert, will be invaluable additions to our already strong Board as we progress toward important inflection points. Welcome to Oculis!   For full bios and additional detail on Oculis’ Annual General Meeting, including important information on forward-looking statements, see our press release here: https://bit.ly/3VkeKwz   #eyehealth #ophthalmology #biotech #biopharma #eyedisease #leadership 

We are thrilled to ring the Nasdaq opening bell in Iceland! Today marks the commencement of trading on the Nasdaq Iceland Main Market under the ticker symbol “OCS” in addition to our listing in the U.S. on Nasdaq Global Market. Being dual-listed allows a broader range of investors to join us on our journey to fulfil our mission of saving sight and improving eye care.     Additionally, Oculis successfully closed the oversubscribed $59 million equity financing, which includes participation from new Icelandic institutional and existing investors, and extends Oculis’ cash runway until the second half of 2026. We continue to strengthen our financial resources and are well positioned to deliver on value-driving milestones across our innovative pipeline including the topline results from our OCS-02 Phase 2b RELIEF trial anticipated later this quarter.   For additional details, including important information on forward-looking statements, see our press release here: https://bit.ly/4aND6Ea   #eyehealth #ophthalmology #biotech #biopharma #financing #healthcare

It is with immense sadness that we mourn the sudden passing of Prof. Ramin Tadayoni, a revered leader in the field of ophthalmology, who left us while attending a conference in São Paulo, Brazil.   Prof. Tadayoni was a beacon of knowledge and innovation in ophthalmology, dedicated to advancing the understanding and treatment of retinal diseases. His work has advanced science, benefiting patients worldwide and earning him the utmost respect and admiration of the global medical community.    In addition to his scientific achievements, Prof. Tadayoni will be remembered for his kindness, humility, mentorship, and unwavering commitment to education and advancing the field of ophthalmology. He touched the lives of many, from patients to peers and protégés, leaving behind a profound legacy that will continue to inspire and influence for generations to come.   As we mourn his loss, we also celebrate his extraordinary contributions and the indelible mark he has left in the field of ophthalmology and in our hearts. Prof. Tadayoni's vision, passion, and dedication will be sorely missed and never forgotten.   We extend our sincere condolences to his family, friends, and all who knew him. Let us come together in remembering and honoring a true pioneer in ophthalmology, a compassionate mentor, and a dear friend. Prof. Tadayoni's legacy will forever be a part of Oculis and the wider ophthalmology community.   #RaminTadayoni #InMemory #Ophthalmology #Legacy

Yesterday we announced the appointment of Snehal Shah, Pharm. D. as President of Research & Development. Dr. Shah’s joins Oculis from Iveric Bio and brings extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals.   His extensive strategic experience in leading R&D and regulatory functions, and successful track record will play a pivotal role in our efforts to deliver transformative new therapies to patients suffering from eye diseases.   For additional details, including important information on forward-looking statements, see our press release here: https://bit.ly/3JdxhDS   #eyehealth #ophthalmology #biotech #biopharma #leadership #healthcare

On Sunday, Eric Donnenfeld, M.D., presented the positive topline results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place on April 5-8, 2024 in Boston, MA.   The Phase 3 OPTIMIZE-1 trial met its primary endpoints, demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery. Topline data from the second Phase 3 OPTIMIZE-2 trial is anticipated in Q4 2024 and is expected to support NDA submission. If approved, OCS-01 would become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.   For additional details, including important information on forward-looking statements, see our press release here: https://bit.ly/3PTXbQV   #eyehealth #ophthalmology #biotech #biopharma #ASCRS

It was a privilege to join leading ophthalmology experts during Eyecelerator @ASCRS 2024, to discuss the treatment landscape and recent advancements that are accelerating innovation. At Oculis, our innovative and diversified pipeline continues to advance, and we remain laser-focused on delivering our key programs: OCS-01 in DME, OCS-02 in DED and OCS-05 in Acute Optic Neuritis. We are confident and excited as we move into a catalyst-rich 2024 and look forward to updating everyone on the upcoming RELIEF trial readout planned by end of Q2 and the ACUITY trial readout of OCS-05 in Acute Optic Neuritis planned in Q4. Thank you again to the conference organizers for an excellent event! #eyehealth #ophthalmology #biotech #biopharma #eyecelerator #ASCRS

In case you missed it, our management team, together with leading ophthalmology experts, recently discussed key advancements from our ongoing clinical programs during an R&D Day held in New York. We are well positioned to deliver on upcoming milestones in the year ahead and look forward to providing further updates!   Watch the replay here: https://lnkd.in/ehyB_uRD   #eyehealth #ophthalmology #biotech #biopharma #leadership #healthcare #NewYork #eyedisease #DiabeticMacularEdema #DryEyeDisease #clinicaldeveloment